MPTP

• Description :

  MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a brain penetrant dopamine neurotoxin. MPTP can be used to induce Parkinson’s Disease model. MPTP, a precusor of MPP+, induces apoptosis[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H320, H335

• Target :

  Apoptosis; Dopamine Receptor

• Related Pathways :

  Apoptosis; GPCR/G Protein; Neuronal Signaling

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Neurological Disease

• Purity :

  99.78

• Solubility :

  DMSO : 50 mg/mL (ultrasonic; warming)

• Smiles :

  CN1CC=C(CC1)C2=CC=CC=C2

• Molecular Formula :

  C12H15N

• Molecular Weight :

  173.25

• Precautions :

  H302, H315, H320, H335

• References & Citations :

  [1]Langston J W, Irwin I. MPTP Neurotoxicity: An Overview and Characterization of Phases of Toxicity. II. Selective Accumulation of MPP in the Substantia Nigra: A Key to Neurotoxicity (Question) . Life Sci., 1985, 36, No. 3, 201-12.|[2]Hsu K S, et al. Potentiation of MPTP by 4-Phenylpyridine on the Neuromuscular Blockade in Mouse Phrenic Nerve-Diaphragm. Neuropharmacology, 1993, 32, No. 9, 877-83.|[3]Sun XL, et al. Gas1 up-regulation is inducible and contributes to cell apoptosis in reactive astrocytes in the substantia nigra of LPS and MPTP models. J Neuroinflammation. 2016 Jul 8;13 (1) :180.|[4]Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc. 2007;2 (1) :141-51.|[5]Rabaneda-Lombarte N, et al. The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson's disease. J Neuroinflammation. 2021 Apr 6;18 (1) :88.|[6]Lee, et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2019 Jan;26 (2) :213-228.|[7]Zhang QS, et al. Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease. Acta Pharmacol Sin. 2017 Oct;38 (10) :1317-1328.|[8]Hammock BD, et al., A sheep model for MPTP induced Parkinson-like symptoms. Life Sci. 1989;45 (17) :1601-8.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  RT, protect from light

• Scientific Category :

  Reference compound2

• Clinical Information :

  No Development Reported

• Citation 01 :

  Carbohydr Polym. 2025 Oct 3;371:124492.|Fitoterapia. 2024 Jun:175:105908.|ACS Chem Neurosci. 2025 Mar 5;16 (5) :968-980.|AfricArXiv Preprints. 2019 Aug.|Antioxidants (Basel) . 2023 Nov 13;12 (11) :1999.|Biochem Biophys Res Commun. 2020 Jun 11;526 (4) :1013-1020.|Bioelectrochemistry. 2020 Aug;134:107532.|bioRxiv. 2023 Jun 26:2023.06.26.546143.|Brain Res Bull. 2024 May 31:110989.|Brain Res Bull. 2025 Oct 22:232:111595.|Brain Res. 2016 Jul 1:1642:546-552.|Brain Res. 2019 Jul 15:1715:203-212.|Brain Res. 2019 Oct 15:1721:146334.|Brain Res. 2020 Jan 1;1726:146493.|Brain Res. 2020 Nov 1;1746:147023.|Brain‐X. 2025 Jun 27.|Cell Death Dis. 2021 Feb 15;12 (2) :181.|Cell Death Dis. 2019 Dec 16;10 (12) :952. |Cell Death Discov. 2022 May 20;8 (1) :267.|Cell Death Discov. 2025 Jul 29;11 (1) :351.|Cell Mol Neurobiol. 2025 May 29;45 (1) :53.|Charles University. 2024 Jan 29.|Chem Eng J. 2024 Sep 20.|Chem Eng J. 2025 Apr 1.|Chin Med. 2025 Nov 8;20 (1) :185.|CNS Neurosci Ther. 2024 Feb;30 (2) :e14407.|CNS Neurosci Ther. 2025 Oct;31 (10) :e70626.|Exp Neurol. 2024 Dec:382:114958.|Exp Neurol. 2025 Jan:383:115001.|Exp Neurol. 2025 Jan:383:115040.|Food Res Int. 2025 Feb:201:115590. |Front Aging Neurosci. 2023 Jan 25:15:1087823.|Heliyon. 2020 Jul 11;6 (7) :e04425.|Heliyon. 2024 Oct 1;10 (21) :e38822.|IBRO Neurosci Rep. 2021 Nov 27:12:1-11.|Int J Mol Med. 2025 Jun;55 (6) :85.|Int J Mol Sci. 2024 Nov 27;25 (23) :12733.|Int J Mol Sci. 2025 Mar 19;26 (6) :2762.|Int J Pharm. 2020 Mar 15;577:119053.|J Ethnopharmacol. 2024 May 10:325:117857.|J Funct Foods. 2025 Feb.|J Integr Neurosci. 2024 Feb 4;23 (2) :29.|J Med Chem. 2023 Sep 14;66 (17) :12614-12628.|J Nanobiotechnology. 2024 Sep 14;22 (1) :567.|J Neuroinflammation. 2024 Apr 12;21 (1) :92.|J Nutr Biochem. 2025 May 12:109954.|J Transl Med. 2025 Jul 11;23 (1) :781.|J Vis Exp. 2025 Aug 29: (222) .|Microchem J. 2024 Nov.|Mol Neurobiol. 2025 Apr 21.|Mol Neurobiol. 2025 May 22.|Nephrology (Carlton) . 2025 Feb;30 (2) :e70006.|Neurosci Bull. 2025 Nov 18.|Neurosci Lett. 2021 Jan 10;741:135493.|Neurosci Lett. 2025 Aug 9:865:138351.|Neurotherapeutics. 2025 Feb 3:e00538.|Neurotox Res. 2020 Jun;38 (1) :27-37.|Neurotox Res. 2023 Jun;41 (3) :212-223.|Pharmaceutics. 2022 Aug 18;14 (8) :1731.|Pharmacol Biochem Behav. 2019 Feb:177:1-11.|Res Sq. 2024 Sep 08.|Res Sq. 2025 Apr 24.|Research Square Preprint. 2021 Jun.|Research Square Preprint. 2024 Apr 17.|Sci Rep. 2025 Apr 15;15 (1) :13027.|Sci Rep. 2025 Apr 8;15 (1) :11947.|Sci Rep. 2025 Jan 25;15 (1) :3190.|Signal Transduct Target Ther. 2021 Feb 24;6 (1) :77.|Talanta. 2025 May 15:295:128302.|Toxicol Sci. 2020 Oct 1;177 (2) :506-520.|University of Szeged. Department of Neurology Faculty of Medicine. 2020 Dec.

• CAS Number :

  [28289-54-5]